We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bbi Hldgs | LSE:BBI | London | Ordinary Share | GB00B00M4S16 | ORD 2.5P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 185.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 185.00 | GBX |
Bbi Holdings (BBI) Share Charts1 Year Bbi Holdings Chart |
|
1 Month Bbi Holdings Chart |
Intraday Bbi Holdings Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/2/2008 | 09:02 | BBI charts and news 2007 | 76 |
| 18/11/2006 | 12:14 | BBI - An opportunity | 88 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 14/1/2008 05:43 by alftupper There is a natural arbitrage between the acquirer's stock price and the share offer price - the see through price by accepting the share offer is about 220p. So fancy dan hedge fund managers can buy BBI and short IMI and automatically lock in a gain. |
Posted at 11/1/2008 21:43 by fridgefraser Can any one explain what is going on with this share, if the cash offer price is 185, why on earth has the share jumped to over 210? is there something i am not aware of, how will this affect the proposed takeover? FF |
Posted at 13/12/2007 08:49 by silverfern Best get your W8-BEN forms ready if you want the share dealIMA have a market cap of $3bn so I suggest BBI won't rate as much within that the Directors won't be ther for long. It made a loss of $50m on revenues of $150m in Q2 so I guess it needs an acquisition strategy to prop its share pirce up, and it has one. THe offer comes when the shares are up three times from two years ago, so be carefu IMHO. IMA is flying but on jam tomorrow. |
Posted at 12/12/2007 06:02 by alftupper It is not much of a premium but it is on a high rating and i think any slippage would have resulted in a share price significantly below 160p and that slippage could be inflicted by IMI |
Posted at 11/12/2007 15:39 by slapdash Acquiring company worth abou $3.4bn so I very much doubt this won't go ahead.... if the stock price of Inverness goes up then presumably so will BBI as it becomes preferable to hold on to their stock.... also if they are allowed makes sense for Inverness to buy in the market at any price below 195pence as that is lower than they are paying for BBI in their stock... I don't know if they are permitted by takeover rules though..... and does depend on Inverness' stock not falling much... the below link allows one to check their stock:12.8million shares traded so far today is about 30% of the company..... of course we should divide by two if the sellers equate to the buyers which would mean that today 15% of the company has changed hands... I'm guessing this is the bidder increasing their stake... or could be arbs taking a position but I think this is unlikley in a small stock.... question is how existing shareholders feel... I think this is a low ball offer but that doesn't mean that in these markets it won't go through without any increase in price.. Slapper |
Posted at 11/12/2007 14:01 by slapdash One thing I would say is that appears the acquirer is very serious about getting the company as the cash or stock offer means shareholders in BBI have lots of choice and so will be happy either way.... I just think they really aren't paying much of a premium considering this company had a stock price of 180p not so long ago.. slap |
Posted at 11/12/2007 11:51 by slapdash not much of a preimium to the current stock price really.... bit disappointing as the stock woudl probably be exceedign the bid price and running away from it in about a year.... wonder how BBI's shareholders feel about it... trouble is the guy's bidding have such a big stake I doubt anyone else will come in..Slapper |
Posted at 11/6/2007 15:08 by geofft I was very pleasantly surprised at the BBI share price movement around the takeover completion time. Like you, I had been expecting a price drop due to the inevitable forced ISA-holder selling, and had even considered selling my THE in the market before the completion. Glad I didn't now, but it seems the longer I invest the less it all makes sense!!! |
Posted at 28/1/2007 19:36 by shuisky Stegrego-Thanks.Sivadnoj-AFAICS (and I'm happy to be corrected) BBI would issue the shares to IMI and existing shareholders would therefore see their holdings diluted by 25% IMHO it's a good practice to dilute the forecast EPS of BBI by 25% in order to factor this in. The T & G (house broker) forecast should have the licence fees factored into estimates. Fellowes2- u r right that they could go for a placing or try and borrow. But IMHO, placing/borrowing 10m is a big 'ask' for a company (BBI) of mkt cap of 38m. Especially, considering that the 7.5m (IMI) unsecured convertible loan was for the acquisitions. With regards the customers issue. You have to bare in mind that the IMI deal gives BBI's customers access to IMI patents, and also means that-if they work with BBI-they won't run the risk of having their products patents challenged by IMI. IMI has a dominant position in the IP of lateral flow testing, and working with BBI means that theycan ensure a worry-free commercialisation of product. For example, look at the Verax deal... 'Under the terms of the agreement BBI will manufacture Verax's PGD Platelet test for the global marketplace. The value of this contract in the next two years is forecast to be in excess of $1.5M. In addition BBI will receive a start up fee of US$600,000, payable in 3 instalments; $100,000 on FDA approval and then $250,000 on each anniversary of the approval.' BBI were working with Verax on this product since 2002. The deal is exclusive. and... 'Verax Biomedical Inc., a leading developer of rapid tests for detecting bacterial contaminants in blood cells and tissue, has signed a 10-year agreement with British Biocell International (BBI) to manufacture the Verax Platelet PGD(R) Test. Under terms of the agreement, BBI could produce as many as 50 million tests and will establish a second manufacturing facility to handle Verax production. The agreement comes in anticipation of strong worldwide demand for the Platelet PGD Test and follows the recent Verax announcement of an exclusive worldwide distribution agreement with Abbott Diagnostics to market and distribute the test, which is currently being evaluated in clinical trials.' ...so I don't consider it likely that the likes of Verax will suddenly pull out. BBI is more than just a contract manufacturer, it has access to IMI patents, and that relationship is critical to understanding the co. There ARE downside risks. IMHO, these pertain to the usual acquisition risk/reward issues. Clinical trialling of Verax platelet. The success of Abbott Labs in distributing the platelet. FDA granting approval of the transfer of technology from IMI to BBI. These things can be delayed. |
Posted at 18/10/2006 23:38 by melody9999 any views folks - are we likely to see the share price slip back to 125p on the back of this release??BBI Holdings PLC 17 October 2006 BBI HOLDINGS PLC Secures acquisition financing from world leader in rapid diagnostic testing BBI Holdings Plc ("BBI"), the AIM listed developer and manufacturer of rapid result diagnostic tests for the point of care market, announced today it has secured a financing commitment to accelerate the growth of the Company from Inverness Medical Innovations Inc. ("IMI") of up to £7.5m by way of an unsecured convertible loan. The loan will be convertible at BBI's discretion for the purpose of financing defined acquisition objectives at any point up through the expiration of its term on 31 March 2007 based on a strike price of 125p. Julian Baines, Managing Director of BBI made the following statement; "We are very happy that IMI, the industry leader in Point of Care, has shown further support to BBI through its commitment of funds that will enable BBI's growth to be significantly accelerated and we look forward to a continued successful working relationship with IMI. The availability of the acquisition finance facility has the potential to achieve a stepped-change in the activities of BBI as it seeks bolt-on acquisitions to scale-up its already successful growth strategy." |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
